Associate Professor Justin Chu's Representative Publications (as of 14 July 2026):

1. Lew RZZ, Tay DJW, Ong JWX, Low JH, Liu J, Wang DY, Chu JJH, Andiappan AK, Tan KS, Chow VTK (2026) Combination of Remdesivir and Ivermectin Exerts Highly Potent and Synergistic Antiviral Activity Against Murine Coronavirus and SARS-CoV-2 Infections. ***Cells*** 2026 Jun 24;15(13):1146. https://doi.org/ 10.3390/cells15131146. [JCR IF: 5.2 (2 year 2025-2026)] (SJR 2024:Q1)

2. Fong YD, Yogarajah T, Khoo XW, Chan YS, Mohameed JBH, Neo A, Yi B, Chu JJH (2026) Preclinical evaluation of GW406108X, a broad-spectrum therapeutic blocking ULK1/2 mediated autophagy to inhibit enterovirus replication. ***Acta Pharmaceutica Sinica B*** 1 July 2026 https://doi.org/10.1016/j.apsb.2026.06.052 [JCR IF: 14.6 (2 year 2025-2026)] (SJR 2024:Q1)

3. Hassandarvish P, Oo A, Teoh BT, Sam SS, Rodrigues GOL, Queiroz-Junior CM, Costa VV, Min N, Khorrami M, Yueh A, Chu JJH, Texeira MM, AbuBakar S, Zandi K (2026) Bridging the gap towards a novel antiviral therapeutic against dengue virus with major flavonoids from Scutellaria baicalensis. ***Antiviral Research*** 2026 Mar 5:106394. https://doi: 10.1016/j.antiviral.2026.106394. [JCR IF: 4.00 (2 year 2025-2026)] (SJR 2024:Q1)

4. Pi MF, Liao WC, Li XY, Cheng MH, Tsai CE, Lai YC, Lin HH, Chuang YC, Tseng CK, Lin YS, Chang CP, Ho TS, Syu GD, Yeh TM, Wang JR, Chu JJH, Wan SW (2026) A Multivalent Dengue Fusion Protein ΔcNS1-cEDIII-ΔnNS3 Confers Cross-Serotype Protection and Durable Immunity in Mice. ***Journal of Medical Virology*** 2026 Feb;98(2):e70822. https://doi: 10.1002/jmv.70822. [JCR IF: 4.60 (2 year 2025-2026)] (SJR 2024:Q1)

5. Lai YW, Cheng D, Huang SW, Chu JJH, Yeh MT, Chang CF, Chen CY, Wang JR (2026) Impact of genomic variations found in Enterovirus A71 virus population on viral properties and disease severity. ***Journal of Medical Virology*** 2026 Feb;98(2):e70814. https:// doi: 10.1002/jmv.70814. [JCR IF: 4.60 (2 year 2025-2026)] (SJR 2024:Q1)

6. Loh SN, Liao D, Lee RCH, Chu JJH, Kini RM, Mok YK, Koh CY, Sivaraman J (2025) Aedes aegypti salivary protein LTRIN activates pro-inflammatory genes in human dermal fibroblasts to counter mosquito-borne viral challenges. ***Virulence*** 2025 Dec;16(1):2580163. https:// doi: 10.1080/21505594.2025.2580163. Epub 2025 Nov 3. [JCR IF: 5.40 (2 year 2025-2026)] (SJR 2024:Q1)

7. Yang SL, DeFalco L, Wang S, Wong YH, Han J, Mok CK, Tan KY, Lim SY, Zhao Z, Zhang Y, Lim JJA, Xiang JS, Sobota R, Wang LF, Chu JJH, Merits A, Huber RG, Wan Y (2025) A conserved long-range RNA interaction in SARS-CoV-2 recruits ADAR1 to enhance virus proliferation. ***Nature Communications*** 2025 Sep 26;16(1):8460. https:// doi: 10.1038/s41467-025-63297-2 [JCR IF: 15.70 (2 year 2025-2026)] (SJR 2024:Q1)

8. Amali AA, Tay DJW, Seow Y, Loh M, Ravikumar S, Yu JJ, Loong SSE, Fong SW, Lee CJM, Lim JJC, Gan LH, Koh WLC, Ding Y, Sam QH, Tan Z, Tan RYM, Lua CB, Chu JJH, Singhal A, Prabhakar S, Chng WJ, Renia L, Lye DCB, Ng LFP, Tan KS, Foo R, Lee CCM, Young B, Chai LYA (2025) Novel NUDCD1 gene variant predisposes to severe COVID-19 disease in Asians through modulation of antiviral DHX15- and MAVS-mediated signalling. ***Frontiers in Immunology*** 2025 Jun 4:16:1581293. https:// doi: 10.3389/fimmu.2025.1581293. [JCR IF: 5.90 (2 year 2025-2026)] (SJR 2024:Q1)

9. Ho WS, Yogarajah T, Mohameed JBH, Fong DY, Cheong DHJ, Wong YH, Chu JJH, Chai CLL (2025) Mutagenesis-Guided Target Identification Reveals the Protein-Binding Domain of Nsp14 in Coronaviruses as the Target of a Labdane-Oxindole Compound. ***ACS Infectious Diseases*** 2025 Apr 10 https:// doi: 10.1021/acsinfecdis.4c00965. [JCR IF: 3.80 (2 year 2025-2026)] (SJR 2024:Q1)

10. Tan KS, Liu J, Andiappan AK, Lew ZZR, He TT, Ong HH, Tay DJW, Aw ZQ, Yi B, Fauzi AM, Yogarajah T, Lee CPC, Chu JJH, Chow VT, Prabakaran M, Wang DY (2025) Unique Immune and Other Responses of Human Nasal Epithelial Cells Infected with H5N1 Avian Influenza Virus Compared to Seasonal Human Influenza A and B Viruses. ***Emerging Microbes & Infections*** Vol. 14 2025 Apr 7 https://doi: 10.1080/22221751.2025.2484330 [JCR IF: 7.50 (2 year 2025-2026)] (SJR 2024:Q1)

11. Wang K, Lee SXY, Jaladanki CK, Ho WS, Chu JJH, Fan H, Chai CLL (2025) Identification of Small-Molecule Inhibitors for Enterovirus A71 IRES by Structure-Based Virtual Screening. ***Journal of Chemical Information and Modeling*** 2025 Mar 1. https://doi: 10.1021/acs.jcim.4c01903 [JCR IF: 5.30 (2 year 2025-2026)] (SJR 2024:Q1)

12. Hee JR, Cheng D, Chen YH, Wang SH, Chao CH, Huang SW, Ling P, Wan SW, Chang CP, Chu JJH, Yeh TM, Wang JR (2025) A non-structural protein 1 substitution of dengue virus enhances viral replication by interfering with the antiviral signaling pathway. ***Journal of Biomedical Science*** 2025 Feb 20;32(1):25. https://doi: 10.1186/s12929-024-01116-4. [JCR IF: 12.10 (2 year 2025-2026)] (SJR 2024:Q1)

13. Tan YW, Bok CF, Lim BJF, Kong LY, Goo KS, Ishida Y, Liu J, Chua CS, Chu JJH (2025) Non-enveloped virus inactivation potency of sodium dodecyl sulfate with citric and glutamic acids. ***Frontiers in Microbiology*** 19 February 2025; Volume 16 - 2025 https://doi.org/10.3389/fmicb.2025.1535404 [JCR IF: 4.50 (2 year 2025-2026)] (SJR 2024:Q1)

14. Ying MKL, Masirevic S, Tan YW, Marzinek JK, Fox SJ, Verma CS, Bond PJ, Ishida Y, Liu J, Chua CS, Chu JJH (2025) Exploring non-alcohol-based disinfectant: virucidal efficacy of arginine and Zinc chloride against feline calicivirus. ***Frontiers in Microbiology*** 13 February 2025; Volume 16 – 2025, https://doi.org/10.3389/fmicb.2025.1550295 [JCR IF: 4.50 (2 year 2025-2026)] (SJR 2024:Q1)

15. Oo A, Borge A, Lee RCH, Salim CK, Wang W, Ricca M, Fong DY, Alonso S, Brown LE, Porco Jr JA, Chu JJH (2025) In Vitro Discovery of a Therapeutic Lead for HFMD From a Library Screen of Rocaglates/Aglains. ***Journal of Medical Virology*** 2025 Feb;97(2):e70228. https://doi: 10.1002/jmv.70228. [JCR IF: 4.60 (2 year 2025-2026)] (SJR 2024:Q1)

16. Xue Y, Xing K, Tham MJR, Li BL, Sikdar N, Leong LP, Lee CH, Chu JJH, Ang WH, Leong DT (2025) Visible light-powered photodynamic antibacterial chlorophyllin-derived metallochlorins. ***Chemical Engineering Journal*** Volume 504, 15 January 2025. https://doi.org/10.1016/j.cej.2024.158345. [JCR IF: 13.20 (2 year 2025-2026)] (SJR 2024:Q1)

17. Cheong DHJ, Yi B, Wong YH, Chu JJH (2025) The Current Progress in the Quest for Vaccines Against the Semliki Forest Virus Complex. ***Medicinal Research Reviews*** 2025 Jan 5. doi: 10.1002/med.22097. https://doi.org/10.1002/med.22097. [JCR IF: 11.60 (2 year 2025-2026)] (SJR 2024:Q1)

18. Yip JQ, Oo A, Ng YL, Chin KL, Tan KK, Chu JJH, AbuBakar S, Zainal N (2024) The role of inflammatory gene polymorphisms in severe COVID-19: a review. ***Virology Journal*** 2024 Dec 20;21(1):327. https://doi.org/10.1186/s12985-024-02597-3. [JCR IF: 3.80 (2 year 2025-2026)] (SJR 2024:Q1)

19. Oo A, Chu JJH (2024) Precision disease management: prognostic biomarker for chronic lung damage in long COVID. ***ERJ Open Research*** 2024 Dec 2; 10(6): 00647-2024; https://doi.org/10.1183/23120541.00647-2024. [JCR IF: 4.00 (2 year 2025-2026)] (SJR 2024:Q1)

20. Abdelbasset M, Saron WA.A, Ma DL, Rathore AP.S., Kozaki T, Zhong CW, Mantri CK, Tan YR, Tung CC, Tey, HL, Chu JJH, Chen JM, Ng LG, Wang HY, Ginhoux F, St. John AL (2024) Differential contributions of fetal mononuclear phagocytes to Zika virus neuroinvasion versus neuroprotection during congenital infection. ***Cell*** 2024 Nov 6:S0092-8674(24)01210-8. http://doi: 10.1016/j.cell.2024.10.028. [JCR IF: 103.30 (2 year 2025-2026)] (SJR 2024:Q1)

21. Lim TYM, Jaladanki CK, Wong YH, Yogarajah T, Fan H, Chu JJH (2024) Tanomastat exerts multi-targeted inhibitory effects on viral capsid dissociation and RNA replication in human enteroviruses. ***EBioMedicine*** 2024 Sep 2:107:105277. http://doi: 10.1016/j.ebiom.2024.105277 [JCR IF: 10.80 (2 year 2025-2026)] (SJR 2024:Q1)

22. Chooi WH, Winanto, Zeng Y, Chery, Lim YP, Lim ZQ, Gautam P, Chu JJH, Loh YH, Alonso S, Ng SY (2024) Enterovirus-A71 Preferentially Infects and Replicates in Human Motor Neurons, Inducing Neurodegeneration by Ferroptosis. ***Emerging Microbes & Infections*** 2024 Jul 17:2382235. http://doi: 10.1080/22221751.2024.2382235. [JCR IF: 7.50 (2 year 2025-2026)] (SJR 2024:Q1)

23. Ng QY, Mahendran V, Lim ZQ, Tan JHY, Wong JJF, Chu JJH, Chow VTK, Sze NSK, Alonso S (2024) Enterovirus-A71 exploits RAB11 to recruit chaperones for virus morphogenesis. ***Journal of Biomedical Science*** 2024 Jun 28;31(1):65. http://doi: 10.1186/s12929-024-01053-2 [JCR IF: 12.10 (2 year 2025-2026)] (SJR 2024:Q1)

24. Tsai YY, Cheng D ,Huang SW, Hung SJ, Wang YF, Lin YJ, Tsai HP, Chu JJH, Wang JR (2024) The molecular epidemiology of a dengue virus outbreak in Taiwan: population wide versus infrapopulation mutation analysis. ***PLoS Neglected Tropical Disease*** 2024 Jun 13;18(6):e0012268. https://doi: 10.1371/journal.pntd.0012268. [JCR IF: 3.40 (2 year 2025-2026)] (SJR 2024:Q1)

25. Zhou Y, Zhou C, Wang K, Qiu Q, Cheng Y, Li Y, Cui P, Liang L, Li P, Deng X, Wang L, Zheng W, Gong H, Wang F, Xu M, Chu JJH, Turtle L, Yu H (2023) Diagnostic performance of different specimens in detecting enterovirus A71 in children with hand, foot and mouth disease. ***Virologica Sinica*** Volume 38, Issue 2, April 2023, Pages 268-275 https://doi.org/10.1016/j.virs.2022.11.004 [JCR IF: 3.32 (2 year 2025-2026)] (SJR 2024:Q2)

26. Jiao H, James SJ, Png CW, Cui C, Li H, Li L, Chia WN, Min N, Li W, Claser C, Rénia L, Wang H, Chen MIC, Chu JJH, Tan KSW, Deng Y, Zhang Y (2024) DUSP4 modulates RIG-I- and STING-mediated IRF3-type I IFN response. ***Cell Death & Differentiation*** 2024 Feb 21. https://doi: 10.1038/s41418-024-01269-7. [JCR IF: 15.40 (2 year 2025-2026)] (SJR 2024:Q1)

27. Ho SX, Law JH, Png CW, Alberts R, Zhang Y, Chu JJH & Tan KK (2024) Alterations in colorectal cancer virome and its persistence after surgery. ***Scientifc Reports*** 2024 Feb 3;14(1):2819.doi: 10.1038/s41598-024-53041-z. [JCR IF: 3.90 (2 year 2025-2026)] (SJR 2024:Q1)

28. Ravindran S, Kong HY, Joseph T, Chu JJH (2023) Comprehensive emergency management programme of NUS Medicine Biosafety Level 3 Core Facility. ***Journal of Environment and Safety*** Volume 14(2023) https://doi.org/10.11162/daikankyo.E22PROCP18.

29. Chen H, Phuektes P, Yeo LS, Wong YH, Lee RCH, Yi B, Hou X, Liu S, Cai Y, Chu JJH (2023) Attenuation of Neurovirulence of Chikungunya Virus by a Single Amino Acid Mutation in Viral E2 Envelope Protein. ***Journal of Biomedical Science*** 2024 Jan 17;31(1):8. doi: 10.1186/s12929-024-00995-x. [JCR IF: 12.10 (2 year 2025-2026)] (SJR 2024:Q1)

30. Tan YW, Teo FMS, Ler SG, Alli-Shaik A, Nyo M, Chong CY, Tan NWH, Wang RYL, Gunaratne J, Chu JJH (2023) Potential relevance of salivary legumain for the clinical diagnostic of hand, foot, and mouth disease. ***Journal of Medical Virology*** 2023 Nov;95(11):e29243.doi: 10.1002/jmv.29243. [JCR IF: 4.60 (2 year 2025-2026)] (SJR 2024:Q1)

31. Putri GN , Gudla CS, Singh M, Ng CH, Idris FFH, Oo Y, Tan JHY, Wong JFJ, Chu JJH, Selvam V, Selvaraj SS, Shandil RK, Narayanan S, Alonso S (2023) Expanding the anti-flaviviral arsenal: Discovery of a baicalein-derived Compound with potent activity against DENV and ZIKV. ***Antiviral Research*** 2023 Nov 7:220:105739. doi: 10.1016/j.antiviral.2023.105739. [JCR IF: 4.00 (2 year 2025-2026)] (SJR 2024:Q1)

32. Chin WX, Kong HY, Zhu IXY, Teo ZY, Faruk R, Lee RCH, Ho SX, Aw ZQ, Yi BW, Hou XJ, Tan AKY, Yogarajah T, Huber RG, Cai Y, Wan Y, Chu JJH (2023) Flavivirus genome recoding by codon optimisation confers genetically stable *in vivo* attenuation in both mice and mosquitoes. ***PLOS Pathgens*** October 26, 2023 https://doi.org/10.1371/journal.ppat.1011753 [JCR IF: 4.90 (2 year 2025-2026)] (SJR 2024:Q1)

33. Jayasinghe MK, Gao C, Yap G, Yeo BZJ , Vu LT, Tay DJW, Loh WX, Aw ZQ, Chen H, Phung DC , Hoang DV, Prajogo RC, Hooi L, Lim FQ, Pirisinu M, Mok CK, Lim KW, Tang SJ, Tan KS, Chow EKH, Chen L, Phan AT, Chu JJH, Le MT (2023) Red Blood Cell-Derived Extracellular Vesicles Display Endogenous Antiviral Effects and Enhance the Efficacy of Antiviral Oligonucleotide Therapy. ***ACS Nano*** 2023 Oct 18. https://doi: 10.1021/acsnano.3c06803. [JCR IF: 16.00 (2 year 2025-2026)] (SJR 2024:Q1)

34. Loe MWC , Lee RCH, Chin WX, Nyo Min, Teo ZY, Ho SX, Yi BW, Chu JJH (2023) Chelerythrine chloride inhibits Zika virus infection by targeting the viral NS4B protein. ***Antiviral Research*** 2023 Oct https://doi.org/10.1016/j.antiviral.2023.105732. [JCR IF: 4.00 (2 year 2025-2026)] (SJR 2024:Q1)

35. Cheong DHJ, Yogarajah T, Wong YH, Arbrandt G, Westman J, Chu JJH. (2023) CUR-N399, a PI4KB inhibitor, for the treatment of Enterovirus A71 infection. ***Antiviral Research*** 2023 Aug 30;105713. https://doi: 10.1016/j.antiviral.2023.105713. [JCR IF: 4.00(2 year 2025-2026)] (SJR 2024:Q1)

36. Keng CT, Yogarajah T, Lee RCH, Muhammad IBH, Chia BS, Vasandani SR, Lim DS, Guo K, Wong YH, Mok CK, Chu JJH, Chew WL. (2023) AAV-CRISPR-Cas13 eliminates human enterovirus and prevents death of infected mice. ***EBioMedicine*** 2023 Jun 28;93:104682. https://doi: 10.1016/j.ebiom.2023.104682. [JCR IF: 10.80 (2 year 2025-2026)] (SJR 2024:Q1)

37. Yi BW, Chew BXZ, Chen HX , Lee RCH, Fong YHD, Chin WX, Mok CK and Chu JJH. (2023) Antiviral Activity of Catechin against Dengue Virus Infection. ***Viruses*** 2023 Jun 15;15(6):1377. https:// doi: 10.3390/v15061377. [JCR IF: 3.50 (2 year 2025-2026)] (SJR 2024:Q1)

38. Lin DCD, Weng SC, Tsao PN, Chu JJH and Shiao SH. (2023) Co-infection of dengue and Zika viruses mutually enhances viral replication in the mosquito Aedes aegypti. ***Parasites & Vectors*** 2023 May 11;16(1):160, https://doi: 10.1186/s13071-023-05778-1. [JCR IF: 3.5 (2 year 2025-2026)] (SJR 2024:Q1)

39. Boonyasuppayakorn S, Saelee T, Huynh TNT, Hairani R, Hengphasatporn K, Loeanurit N, Cao V, Vibulakhaophan V, Siripitakpong P, Kaur P, Chu JJH, Tunghirun C, Choksupmanee O, Chimnaronk S, Shigeta Y, Rungrotmongkol T, Chavasiri W (2023) The 8-bromobaicalein inhibited the replication of dengue, and Zika viruses and targeted the dengue polymerase ***Scientific Reports*** Mar 25 2023;13(1):4891. https://doi.org/10.1038/s41598-023-32049-x [JCR IF: 3.90 (2 year 2025-2026)] (SJR 2024:Q1)

40. Liu LT, Tsai JJ, Chu JJH, Chen CH, Chen LJ, Lin PC, Tsai CY, Hsu MC, Chuang WL, Hwang SJ, Chong IW. (2023) The identification and phylogenetic analysis of SARS-CoV-2 delta variants in Taiwan. ***Kaohsiung Journal of Medical Sciences*** Mar 23 2023. https://doi.org/10.1002/kjm2.12665 [JCR IF: 2.996(2 year 2021-2022)] (SJR 2023:Q2)

41. Tan KS , Ong SWX, Koh MH, Tay DJW, Aw DZH, Nah YW, Abdullah MRB, Coleman KK, Milton DK, Chu JJH , Chow VTK, Tambyah PA, Tham KW. (2023) SARS-CoV-2 Omicron variant shedding during respiratory activities. ***International Journal of Infectious Diseases*** March 2023 https://doi.org/10.1016/j.ijid.2023.03.029. [JCR IF: 4.3 (2 year 2025-2026)] (SJR 2024:Q1)

42. Wu KX, Yogarajah T, Loe MWC, Kaur P, Lee RCH, Mok CK, Wong YH, Phuektes P, Yeo LS, Chow VTK, Tan YW, Chu JJH (2023) The host-targeting compound peruvoside has a broad-spectrum antiviral activity against positive-sense RNA viruses. ***Acta Pharmaceutica Sinica B*** March 2023 https://doi.org/10.1016/j.apsb.2023.03.015. [JCR IF: 14.60 (2 year 2025-2026)] (SJR 2024:Q1)

43. Ju B, Zhang Q, Wang ZY, Aw ZQ, Chen P, Zhou B, Wang RK, Ge XY , Lv QN , Cheng Lin, Zhang R, Wong YH, Chen HX, Wang HY, Shan SS, Liao XJ, Shi XL, Liu L, Chu JJH , Wang XQ , Zhang Z and Zhang LQ (2023) Infection with wild-type SARS-CoV-2 elicits broadly neutralizing and protective antibodies against omicron subvariants. ***Nature Immunology*** 2023 https://doi.org/10.1038/s41590-023-01449-6. [JCR IF: 27.60 (2 year 2025-2026)] (SJR 2024:Q1)

44. Mok CK, Ng YL, Ahidjo BA, Aw ZQ, Chen HX, Wong YH, Lee RCH, Loe MWC, Liu J, Tan KS, Kaur P, Wang DY, Hao EW, Hou XT, Tan YW, Deng JG and Chu JJH (2023) Evaluation of In Vitro and In Vivo Antiviral Activities of Vitamin D for SARS-CoV-2 and Variants. ***Pharmaceutics*** 2023, *15*(3),925; https://doi.org/10.3390/pharmaceutics15030925. [JCR IF: 5.50 (2 year 2025-2026)] (SJR 2024:Q1)

45. Loeanurit N, Tuong TL , Nguyen VK , Vibulakhaophan V, Hengphasatporn K, Shigeta Y, Ho SX, Chu JJH, Rungrotmongkol T, Chavasiri W, Boonyasuppayakorn S (2023) Lichen-Derived

Diffractaic Acid Inhibited Dengue Virus Replication in a Cell-Based System. ***Molecules*** 2023 Jan 18;28(3):974. doi: 10.3390/molecules28030974. [JCR IF: 4.60 (2 year 2025-2026)] (SJR 2024:Q1)

46. Tan KS, Ang AXY, Tay DJW, Somani J, Ng AJY, Peng LL, Chu JJH, Tambyah PA and Allen DM (2023). Detection of hospital environmental contamination during SARS-CoV-2 Omicron predominance using a highly sensitive air sampling device. ***Frontiers in Public Health***, 10 January 2023, https://doi.org/10.3389/fpubh.2022.1067575. [JCR IF: 3.40 (2 year 2025-2026)] (SJR 2024:Q1)

47. Li MX, Ren YF, Aw ZQ, Chen B, Yang ZQ, Lei YQ, Cheng L, Liang QT, Hong JX, Yang YL, Chen J, Wong YH, Wei J, Shan SS, Zhang SY, Ge JW, Wang RK, Dong JZJ, Chen YX, Shi XL, Zhang Q, Zhang Z, Chu JJH, Wang XQ & Zhang LQ. (2022) Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.4/5 and diverse sarbecoviruses. ***Nature Communications*** 13, Article number: 7957. https://doi.org/10.1038/s41467-022-35642-2. [JCR IF: 15.70 (2 year 2025-2026)] (SJR 2024:Q1)

48. Zhou YH, Zhou CC, Wang K, Qiu Q, Cheng YB, Li Y, Cui P, Liang L, Li Peng, Deng XW, Wang LL, Zheng W, Gong H, Wang F, Xu M, Chu JJH, Turtle L, Yu HJ. (2022) Diagnostic performance of different specimens in detecting enterovirus A71 in children with hand, foot and mouth disease. ***Virologica Sinica***, 2022 Nov 10;S1995-820X(22)00188-2. doi: 10.1016/j.virs.2022.11.004. [JCR IF: 3.32 (2 year 2025-2026)] (SJR 2024:Q2)

49. Aw ZQ, Mok CK, Wong YH, Chen H, Mak TM , Lin RTP, Lye DC, Tan KS and Chu JJH. (2022) Early pathogenesis profiles across SARS-CoV-2 variants in K18-hACE2 mice revealed differential triggers of lung damages. ***Frontiers in Immunology*** 13:950666. https://doi.org/10.3389/fimmu.2022.950666. [JCR IF: 5.90 (2 year 2025-2026)] (SJR 2024:Q1)

50. Liew OW, Fanusi F, Ng JYX, Ahidjo BA, Ling SSM, Lilyanna S, Chong JPC, Lim AES, Lim WZ, Ravindran S, Chu JJH, Lim SL and Richards AM. (2022) Immunoassay-Compatible Inactivation of SARS-CoV-2 in Plasma Samples for Enhanced Handling Safety. ***ACS Omega*** 2022, 7, 29, 25510–25520, https://pubs.acs.org/doi/10.1021/acsomega.2c02585. [JCR IF:4.30 (2 year 2025-2026)] (SJR 2024:Q1)

51. Cheng D, Huang SW, Chin WX, Hung SJ, Tsai HP, Chu JJH, Chao CH and Wang JR. (2022) Impact of Intrahost NS5 Nucleotide Variations on Dengue Virus Replication. ***Frontiers in Microbiology***, July 2022, https://doi.org/10.3389/fmicb.2022.89420. [JCR IF: 4.50 (2 year 2025-2026)] (SJR 2024:Q1)

52. Zhou Y, Zhou J, Yang J, Qiu Q, Wang L, Yang J, Li Y, Liang L, Cui P, Cheng Y, Zheng W, Shi H, Gong H, Wang K, Zhou C, Chu JJH and Yu H. (2022) Comparison of Neutralizing Antibody Response Kinetics in Patients with Hand, Foot, and Mouth Disease Caused by Coxsackievirus A16

or Enterovirus A71: A Longitudinal Cohort Study of Chinese Children, 2017–2019. ***Journal of Immunology***, July, 2022, ji2200143; DOI: https://doi.org/10.4049/jimmunol.2200143. [JCR IF: 3.40 (2 year 2025-2026)] (SJR 2024:Q1)

53. Warrier T, El Farran C, Zeng Y, Ho BSQ, Bao Q, Zheng ZH, Bi X, Ng HH, Ong DST, Chu JJH, Sanyal A, Fullwood MJ, Collins JJ, Li H, Xu J and Loh YH. (2022) SETDB1 acts as a topological accessory to Cohesin via an H3K9me3-independent, genomic shunt for regulating cell fates. ***Nucleic Acids Research***, July, 2022, https://doi.org/10.1093/nar/gkac531. [JCR IF: 13.10 (2 year 2025-2026)] (SJR 2024:Q1)

54. Wang R, Zhang Q, Zhang R, Aw ZQ, Chen P, Wong YH, Hong J, Ju B, Shi X, Ding Q, Zhang Z, Chu JJH and Zhang L. (2022) SARS-CoV-2 Omicron Variants Reduce Antibody Neutralization and Acquire Usage of Mouse ACE2. ***Frontiers in Immunology***, June, 2022 https://doi.org/10.3389/fimmu.2022.854952. [JCR IF: 5.90 (2 year 2025-2026)] (SJR 2024:Q1)

55. Fong YD, Chu JJH. (2022) Natural products as Zika antivirals. ***Medicinal Research Reviews*** 2022 May 20, https://doi.org/10.1002/med.21891. [JCR IF: 11.60 (2 year 2025-2026)] (SJR 2024:Q1)

56. Yeo H, Chong CWH, Chen EWH, Lim ZQ, Ng QY, Yan B, Chu JJH , Chow VTK, Alonso S. (2022) A Single Amino Acid Substitution in Structural Protein VP2 Abrogates the Neurotropism of Enterovirus A-71 in Mice. ***Frontiers in Microbiology.*** 13:821976, https://doi.org/ 10.3389/fmicb.2022.821976. [JCR IF: 4.50 (2 year 2025-2026)] (SJR 2024:Q1)

57. Wu Z, Chan B, Low J, Chu JJH, Hey HWD, Tay A. (2022) Microbial resistance to nanotechnologies: An important but understudied consideration using antimicrobial nanotechnologies in orthopaedic implants. ***Bioactive Materials.*** 16:249 – 270, https://doi.org/ 10.1016/j.bioactmat.2022.02.014. [JCR IF: 20.30 (2 year 2025-2026)] (SJR 2024:Q1)

58. Tay JW, Lew ZZ, Chu JJH and Tan KS. (2022) Uncovering Novel Viral Innate Immune Evasion Strategies: What Has SARS-CoV-2 Taught Us? ***Frontiers in Microbiology.*** 13:844447, https://doi.org/10.3389/fmicb.2022.844447. [JCR IF: 4.50 (2 year 2025-2026)] (SJR 2024:Q1)

59. Banerjee S, Chin WX, Chu JJH. (2022). miR-573 rescues endothelial dysfunction during dengue infection under PPARγ regulation. ***Journal of Virology.*** 96(6):e0199621, https://doi.org/ 10.1128/jvi.01996-21. [JCR IF: 3.80 (2 year 2025-2026)] (SJR 2024:Q1)

60. Zakir TS, Meng T, Carmen LCP, Chu JJH, Lin RTP, Prabakaran M. (2022) Characterization of a Broadly Neutralizing Monoclonal Antibody against SARS-CoV-2 Variants. ***Viruses.***

14(2):230, https://doi.org/10.3390/v14020230. [JCR IF: 3.50 (2 year 2025-2026)] (SJR 2024:Q1)

61. Tran QTN, Lee RCH, Liu HJ, Ran D, Low VZL, To DQ, Chu JJH, Chai CLL. (2022) Discovery and development of labdane-oxindole hybrids as smallmolecule inhibitors against chikungunya virus infection. ***European Journal of Medicinal Chemistry.*** 230:114110, https://doi.org/10.1016/j.ejmech.2022.114110. [JCR IF: 5.90 (2 year 2025-2026)] (SJR 2024:Q1)

62. Tan JK, Chen R, Lee RCH, Li F, Dai K, Zhou GC, Chu JJH. (2022) Discovery of Novel Andrographolide Derivatives as Antiviral Inhibitors against Human Enterovirus A71. ***Pharmaceuticals.*** 15(2):115, https://doi.org/10.3390/ph15020115. [JCR IF: 4.80 (2 year 2025-2026)] (SJR 2024:Q1)

63. Agiesh Kumar Balakrishna Pillai , Chu JJH, Vignesh Mariappan1 and Aashika Raagavi JeanPierre. (2021) Platelets in the pathogenesis of flavivirus disease. ***Current Opinion in Virology.*** 52:220-228, https://doi.org/10.1016/j.coviro.2021.12.007. [JCR IF: 5.10 (2 year 2025-2026)] (SJR 2024:Q1)

64. Shan S, Mok CK, Zhang S, Lan J, Li J, Yang Z, Wang R, Cheng L, Fang M, Aw ZQ, Yu J, Zhang Q, Shi X, Zhang T, Zhang Z, Wang J, Chu JJH and Zhang L. (2021) A Potent and Protective Human Neutralizing Antibody Against SARS-CoV-2 Variants. ***Frontiers in Immunology***. 12:766821, https://doi.org/10.3389/fimmu.2021.766821. [JCR IF: 5.90 (2 year 2025-2026)] (SJR 2024:Q1)

65. Dai K, Tan JK, Qian W, Lee RCH, Chu JJH, Zhou GC. (2021). Discovery of 14S-(2'-chloro-4'-nitrophenoxy)-8R/S,17-epoxy andrographolide as EV-A71 infection inhibitor. ***Biochemical Pharmacology***. 194:114820, https://doi.org/10.1016/j.bcp.2021.114820. [JCR IF: 5.60 (2 year 2025-2026)] (SJR 2024:Q1)

66. Tan YW, Chu JJH. (2021). Protecting the most vulnerable from hand, foot, and mouth disease. ***The Lancet Infectious Diseases***. 21(3):308-309, https://doi.org/10.1016/S1473-3099(20)30452-7. [JCR IF: 31.00 (2 year 2025-2026)] (SJR 2024:Q1)

67. Ng YL, Salim CK, Chu JJH. (2021). Drug repurposing for COVID-19: Approaches, challenges and promising candidates. ***Pharmacology & Therapeutics.*** 228:107930, https://doi.org/10.1016/j.pharmthera.2021.107930. [JCR IF: 12.50 (2 year 2025-2026)] (SJR 2024:Q1)

68. Huang K, Chu JJH. (2021). Editorial: Evolution & Genomic Adaptation of Emerging and Re-emerging RNA Viruses. ***Frontiers in Microbiology***. 12:777257, https://doi.org/10.3389/fmicb.2021.777257. [JCR IF: 4.50 (2 year 2025-2026)] (SJR 2024:Q1)

69. Tan YW, Yam WK, Kooi RJW, Westman J, Arbrandt G, Chu JJH. (2021) Novel capsid binder and PI4KIIIbeta inhibitors for EV-A71 replication inhibition***. Scientific Reports***. 11(1):9719,

https://doi.org/10.1038/s41598-021-89271-8. [JCR IF: 3.90 (2 year 2025-2026)] (SJR 2024:Q1)

70. Lim ZQ, Ng QY, Oo Y, Chu JJH, Ng SY, Sze SK, Alonso S. (2021) Enterovirus-A71 exploits peripherin and Rac1 to invade the central nervous system***. EMBO Reports.*** 22(6):e51777, https://doi.org/10.15252/embr. 202051777. [JCR IF: 6.20 (2 year 2025-2026)] (SJR 2024:Q1)

71. Tan MTH, Ho SX, Chu JJH, Li D. (2021). Application of virome capture sequencing in shellfish sold at retail level in Singapore***. Letters in Applied Microbiology***. 73(4):486-494, https://doi.org/10.111/lam.13540. [JCR IF: 2.42 (2 year 2025-2026)] (SJR 2024:Q3)

72. Ang AX, Luhung I, Ahidjo BA, Drautz-Moses DI, Tambyah PA, Mok CK, Lau KJ, Tham SM, Chu JJH, Allen DM, Schuster SC. (2021) Airborne SARS-CoV-2 surveillance in hospital environment using high-flowrate air samplers and its comparison to surface sampling. ***Indoor Air.*** 32(1):e12930, https://doi.org/10.1111/ina.12930. [JCR IF: 4.30 (2 year 2025-2026)] (SJR 2024:Q1)

73. Coleman KK, Tay DJW, Sen Tan K, Ong SWX, Son TT, Koh MH, Chin YQ, Nasir H, Mak TM, Chu JJH, Milton DK, Chow VTK, Tambyah PA, Chen M, Wai TK. (2021) Viral Load of SARS-CoV-2 in Respiratory Aerosols Emitted by COVID-19 Patients while Breathing, Talking, and Singing. ***Clinical Infectious Diseases.*** ciab691, https://doi.org/10.1093/cid/ciab691. [JCR IF: 7.30 (2 year 2025-2206)] (SJR 2024:Q1)

74. Tan YL, Tan KSW, Chu JJH, Chow VT. (2021). Combination Treatment With Remdesivir and Ivermectin Exerts Highly Synergistic and Potent Antiviral Activity Against Murine Coronavirus Infection***. Frontiers in Cellular and Infection Microbiology***. 11:700502, https://doi.org/10.3389/fcimb.2021.700502. [JCR IF: 4.80 (2 year 2025-2026)] (SJR 2024:Q1)

75. Ho SX, Min N, Wong EPY, Chong CY, Chu JJH. (2021). Characterization of oral virome and microbiome revealed distinctive microbiome disruptions in paediatric patients with hand, foot and mouth disease. ***npj Biofilms and Microbiomes***. 7(1):19, https://doi.org/10.1038/s41522-021-00190-y. [JCR IF: 9.20 (2 year 2025-2026)] (SJR 2024:Q1)

76. Zheng ZH, Sam TW, Zeng Y, Chu JJH, Loh YH. (2021). Chromatin Regulation in Development: Current Understanding and Approaches. ***Stem Cells International***. 2021:8817581, https://doi.org/10.1155/2021/8817581. [JCR IF: 3.80 (2 year 2025-2026)] (SJR 2024:Q2)

77. Tay CJX, Ta LDH, Ow Yeong YX, Yap GC, Chu JJH, Lee BW, Tham EH. (2021). Role of Upper Respiratory Microbiota and Virome in Childhood Rhinitis and Wheeze: Collegium Internationale Allergologicum Update 2021. ***International Archives of Allergy and***

Immunology. 182(4):265-276, https://doi.org/10.1159/000513325. [JCR IF: 2.13 (2 year 2025-2026)] (SJR 2024:Q2)

78. Min N, Ong YHB, Han AX, Ho SX, Yen EWP, Ban KHK, Maurer-Stroh S, Chong CY, Chu JJH (2021). An epidemiological surveillance of hand foot and mouth disease in paediatric patients and in community: A Singapore retrospective cohort study, 2013-2018. ***PLoS Neglected Tropical Diseases***. 15(2):e0008885, https://doi.org/10.1371/journal.pntd.0008885. [JCR IF: 3.40 (2 year 2025-2026)] (SJR 2024:Q1)

79. Chin WX, Lee RCH, Kaur P, Lew TS, Yogarajah T, Kong HY, Teo ZY, Salim CK, Zhang RR, Li XF, Alonso S, Qin CF, Chu JJH. (2021). A single-dose live attenuated chimeric vaccine candidate against Zika virus. ***npj Vaccines***. 6(1):20, https://doi.org/10.1038/s41541-021-00282-y. [JCR IF: 6.50 (2 year 2025-2026)] (SJR 2024:Q1)

80. Chen H, Min N, Ma L, Mok CK, Chu JJH. (2020). Adenovirus vectored IFN-α protects mice from lethal challenge of Chikungunya virus infection. ***PLoS Neglected Tropical Diseases***. 14(12):e0008910, https://doi.org/10.1371/journal.pntd.0008910. [JCR IF: 3.40 (2 year 2025-2026)] (SJR 2024:Q1)

81. Robinson KS, Teo DET, Tan KS, Toh GA, Ong HH, Lim CK, Lay K, Au BV, Lew TS, Chu JJH, Chow VTK, Wang Y, Zhong FL, Reversade B. (2020). Enteroviral 3C protease activates the human NLRP1 inflammasome in airway epithelia. ***Science***. 370(6521):eaay2002. https://doi.org/10. 1126/science.aay2002. [JCR IF: 45.80 (2 year 2025-2026)] (SJR 2024:Q1)

82. Loe MWC, Hao E, Chen M, Li C, Lee RCH, Zhu IXY, Teo ZY, Chin WX, Hou X, Deng J, Chu JJH (2020). Betulinic acid exhibits antiviral effects against dengue virus infection. ***Antiviral Research***. 184:104954, https://doi.org/10.1016/j.antiviral.2020.104954. [JCR IF: 4.00 (2 year 2025-2026)] (SJR 2024:Q1)

83. Boonyasuppayakorn S, Saelee T, Visitchanakun P, Leelahavanichkul A, Hengphasatporn K, Shigeta Y, Huynh TNT, Chu JJH, Rungrotmongkol T, Chavasiri W. (2020). Dibromopinocembrin and Dibromopinostrobin Are Potential Anti-Dengue Leads with Mild Animal Toxicity. ***Molecules***. 25(18):4154, https://doi.org/10.3390/molecules 25184154. [JCR IF: 4.60 (2 year 2025-2026)] (SJR 2024:Q1)

84. Deng JG, Hou XT, Zhang TJ, Bai G, Hao EW, Chu JJH, Wattanathorn J, Sirisa-Ard P, Soo Ee C, Low J, Liu CX. (2020). Carry forward advantages of traditional medicines in prevention and control of outbreak of COVID-19 pandemic. ***Chinese Herbal Medicines***. 12(3):207-213, https://doi.org/10.1016/j.chmed.2020.05.003. [IF: 8.90(2025-2026)] (SJR 2024:Q1)

85. Goh VSL, Mok CK, Chu JJH. (2020). Antiviral Natural Products for Arbovirus Infections. ***Molecules***. 25(12):2796, https://doi.org/10.3390/molecules25122796. [JCR IF: 4.60 (2 year 2025-2026)] (SJR 2024:Q1)

86. Ahidjo BA, Loe MWC, Ng YL, Mok CK, Chu JJH. (2020). Current Perspective of Antiviral Strategies against COVID-19. ***ACS Infectious Diseases***. 6(7):1624-1634, https://doi.org/10.1021/acsinfecdis.0c00236. [JCR IF: 3.80 (2 year 2025-2026)] (SJR 2024:Q1)

87. Kaur P, Lello LS, Utt A, Dutta SK, Merits A, Chu JJH. (2020). Bortezomib inhibits chikungunya virus replication by interfering with viral protein synthesis. ***PLoS Neglected Tropical Diseases***. 14(5):e0008336, https://doi.org/10.1371/journal.pntd.0008336. [JCR IF: 3.40 (2 year 2025-2026)] (SJR 2024:Q1)

88. Sun J, Yogarajah T, Lee RCH, Kaur P, Inoue M, Tan YW, Chu JJH. (2020). Drug repurposing of pyrimidine analogs as potent antiviral compounds against human enterovirus A71 infection with potential clinical applications. ***Scientific Reports***. 10(1):8159, https://doi.org/ 10.1038/s41598-020-65152-4. [JCR IF: 3.90 (2 year 2025-2026)] (SJR 2024:Q1)

89. Zheng Z, Teo SHC, Arularasu SC, Liu Z, Mohd-Ismail NK, Mok CK, Ong CB, Chu JJ, Tan YJ. (2020). Contribution of Fc-dependent cell-mediated activity of a vestigial esterase-targeting antibody against H5N6 virus infection. ***Emerging Microbes & Infections***. 9(1):95-110, https://doi.org/10.1080/22221751.2019.1708215. [JCR IF: 7.50 (2 year 2025-2026)] (SJR 2024:Q1)

90. Loe MWC, Lee RCH, Chu JJH. (2019). Antiviral activity of the FDA-approved drug candesartan cilexetil against Zika virus infection. ***Antiviral Research***. 172:104637. [JCR IF: 4.00 (2 year 2025-2026)] (SJR 2024:Q1)

91. Gunaseelan S, Wong KZ, Min N, Sun J, Ismail NKBM, Tan YJ, Lee RCH, Chu JJH. (2019). Prunin suppresses viral IRES activity and is a potential candidate for treating enterovirus A71 infection. ***Science Translational Medicine***. 11(516). [JCR IF: 14.60 (2 year 2025-2026)] (SJR 2024:Q1)

92. Lee CHR, Mohamed Hussain K, Chu JJH. (2019). Macropinocytosis dependent entry of Chikungunya virus into human muscle cells. ***PLOS Neglected Tropical Diseases***. 13(8):e0007610. [JCR IF: 3.40 (2 year 2025-2026)] (SJR 2024:Q1)

93. Lee JK, Chui JLM, Lee RCH, Kong HY, Chin WX, Chu JJH. (2019). Antiviral activity of ST081006 against the dengue virus. ***Antiviral Research***. 171:104589. [JCR IF: 4.00 (2 year 2025-2026)] (SJR 2024:Q1)

94. Kandilya D, Maskomani S, Shyamasundar S, Tambyah PA, Shiao Yng C, Lee RCH, Hande MP, Mallilankaraman K, Chu JJH, Dheen ST. (2019). Zika virus alters DNA methylation status of genes involved in Hippo signaling pathway in human neural progenitor cells. ***Epigenomics***. 11(10):1143-1161. [JCR IF: 0.69 (2 year 2025-2026)] (SJR 2024:Q3)

95. Owino CO, Chu JJH. (2019). Recent advances on the role of host factors during non-poliovirus enteroviral infections. ***Journal of Biomedical Science***. 26(1):47. [JCR IF: 12.10 (2 year 2025-2026)] (SJR 2024:Q1)

96. Zhang W, Tan YW, Yam WK, Tu H, Qiu L, Tan EK, Chu JJH, Zeng L. (2019). In utero infection of Zika virus leads to abnormal central nervous system development in mice. ***Scientific Reports***. 9(1):7298. [JCR IF: 3.90 (2 year 2025-2026)] (SJR 2024:Q1)

97. Lee JL, Loe MWC, Lee RCH, Chu JJH. (2019). Antiviral activity of pinocembrin against Zika virus replication. ***Antiviral Research***. 167:13-24. [JCR IF: 4.00 (2 year 2025-2026)] (SJR 2024:Q1)

98. Tan S, Yu CY, Sim ZW, Low ZS, Lee B, See F, Min N, Gautam A, Chu JJH, Ng KW, Wong E (2019). Pomegranate activates TFEB to promote autophagy-lysosomal fitness and mitophagy. ***Scientific Reports***. 9(1):727. [JCR IF: 3.90 (2 year 2025-2026)] (SJR 2024:Q1)

99. Ke Y, Liu WN, Her Z, Liu M, Tan SY, Tan YW, Chan XY, Fan Y, Huang EK, Chen H, En Chang KT, Chan JKY, Hann Chu JJH, Chen Q (2019). Enterovirus A71 Infection Activates Human Immune Responses and Induces Pathological Changes in Humanized Mice. ***Journal of Virology***. 93(3). [JCR IF: 3.80 (2 year 2025-2026)] (SJR 2024:Q1)

100. Bhargava S, Chu JJH, Valiyaveettil S (2018). Controlled Dye Aggregation in Sodium Dodecylsulfate-Stabilized Poly(methylmethacrylate) Nanoparticles as Fluorescent Imaging Probes. ***ACS Omega***. 3(7):7663-7672. [JCR IF: 4.30 (2 year 2025-2026)] (SJR 2024:Q1)

101. Malakar S, Sreelatha L, Dechtawewat T, Noisakran S, Yenchitsomanus PT, Chu JJH, Limjindaporn T (2018). Drug repurposing of quinine as antiviral against dengue virus infection. ***Virus Research***. 255:171-178. [JCR IF: 2.7 (2 year 2025-2026)] (SJR 2024:Q2)

102. Wong KZ, Chu JJH (2018). The Interplay of Viral and Host Factors in Chikungunya Virus Infection: Targets for Antiviral Strategies. ***Viruses***. 10(6). [JCR IF: 3.50 (2 year 2025-2026)] (SJR 2024:Q1)

103. Min N, Sakthi Vale PD, Wong AA, Tan NWH, Chong CY, Chen CJ, Wang RYL, Chu JJH (2018). Circulating Salivary miRNA hsa-miR-221 as Clinically Validated Diagnostic Marker for Hand, Foot, and Mouth Disease in Pediatric Patients. ***EBioMedicine***. 31:299-306. [JCR IF: 10.80 (2 year 2025-2026)] (SJR 2024:Q1)

104. Teo FMS, Nyo M, Wong AA, Tan NWH, Koh MT, Chan YF, Chong CY, Chu JJH (2018). Cytokine and Chemokine Profiling in Patients with Hand, Foot and Mouth Disease in Singapore and Malaysia. ***Scientific Reports***. 8(1):4087. [JCR IF: 3.90 (2 year 2025-2026)] (SJR 2024:Q1)

105. Too IHK, Bonne I, Tan EL, Chu JJH, Alonso S (2018). Prohibitin plays a critical role in Enterovirus 71 neuropathogenesis. ***PLoS Pathogens.*** 14(1):e1006778. [JCR IF: 4.90 (2 year 2025-2026)] (SJR 2024:Q1)

106. Min N, Leong PT, Lee RCH, Khuan JSE, Chu JJH (2018). A flavonoid compound library screen revealed potent antiviral activity of plant-derived flavonoids on human enterovirus A71 replication. ***Antiviral Research*.** 150:60-68. [JCR IF: 4.00 (2 year 2025-2026)] (SJR 2024:Q1)

107. Tan YW, Yam WK, Sun J, Chu JJH (2018). An evaluation of Chloroquine as a broad-acting antiviral against Hand, Foot and Mouth Disease. ***Antiviral Research***. 149:143-149. [JCR IF: 4.00 (2 year 2025-2026)] (SJR 2024:Q1)

108. Morchang A, Lee RCH, Yenchitsomanus PT, Sreekanth GP, Noisakran S, Chu JJH, Limjindaporn T (2017). RNAi screen reveals a role of SPHK2 in dengue virus-mediated apoptosis in hepatic cell lines. ***PLoS One***. 12(11):e0188121. [JCR IF: 2.60 (2 year 2025-2026)] (SJR 2024:Q1)

109. Mirza SB, Lee RCH, Chu JJH, Salmas RE, Mavromoustakos T, Durdagi S (2017). Discovery of selective dengue virus inhibitors using combination of molecular fingerprint-based virtual screening protocols, structure-based pharmacophore model development, molecular dynamics simulations and in vitro studies. ***Journal of Molecular Graphics and Modelling*.** 77:338. [JCR IF: 3.15 (2025-2026)] (SJR 2024:Q2)

110. Wu KX, Chu JJH (2017). Antiviral screen identifies EV71 inhibitors and reveals camptothecin-target, DNA topoisomerase 1 as a novel EV71 host factor. ***Antiviral Research*.** 143:122-133. [JCR IF: 4.00 (2 year 2025-2026)] (SJR 2024:Q1)

111. Reyes M, Piotrowski M, Ang SK, Chan J, He S, Chu JJH, Kah JCY (2017). Exploiting the Anti-Aggregation of Gold Nanostars for Rapid Detection of Hand, Foot, and Mouth Disease Causing Enterovirus 71 Using Surface-Enhanced Raman Spectroscopy. ***Analytical Chemistry*.** 89(10):5373-5381. [JCR IF: 6.70 (2 year 2025-2026)] (SJR 2024:Q1)

112. Chin WX, Ang SK, Chu JJH (2017). Recent advances in therapeutic recruitment of mammalian RNAi and bacterial CRISPR-Cas DNA interference pathways as emerging antiviral strategies. ***Drug Discovery Today*.** 22(1):17-30. [JCR IF: 7.50 (2 year 2025-2026)] (SJR 2024:Q1)

113. Wu KX, Phuektes P, Kumar P, Goh GY, Moreau D, Chow VT, Bard F, Chu JJH (2016). Human genome-wide RNAi screen reveals host factors required for enterovirus 71 replication. ***Nature Communications*****.** 7:13150. [JCR IF: 15.70 (2 year 2025-2026)] (SJR 2024:Q1)

114. Tan YW, Ang MJ, Lau QY, Poulsen A, Ng FM, Then SW, Peng J, Hill J, Hong WJ, Chia CS, Chu JJH (2016). Antiviral activities of peptide-based covalent inhibitors of the Enterovirus 71 3C protease. ***Scientific Reports*****.** 6:33663. [JCR IF: 3.90 (2 year 2025-2026)] (SJR 2024:Q1)

115. Sun J, Ennis J, Turner JD, Chu JJH (2016). Single dose of an adenovirus vectored mouse interferon-α protects mice from lethal EV71 challenge. ***Antiviral Research*****.** 134:207-215. [JCR IF: 4.00 (2 year 2025-2026)] (SJR 2024:Q1)

116. Chen H, Parimelalagan M, Takei F, Hapuarachchi HC, Koay ES, Ng LC, Ho PS, Nakatani K, Chu JJH (2016). Development of 2, 7-Diamino-1, 8-Naphthyridine (DANP) Anchored Hairpin Primers for RT-PCR Detection of Chikungunya Virus Infection. ***PLoS Neglected Tropical Diseases*****.** 10(8): e0004887. [JCR IF: 3.40 (2 year 2025-2026)] (SJR 2024:Q1)

117. Tan YW, Hong WJ, Chu JJH (2016). Inhibition of enterovirus VP4 myristoylation is a potential antiviral strategy for hand, foot and mouth disease. ***Antiviral Research*****.** 133:191-195. [JCR IF: 4.00 (2 year 2025-2026)] (SJR 2024:Q1)

118. Lani R, Hassandarvish P, Shu MH, Phoon WH, Chu JJH, Higgs S, Vanlandingham D, Abu Bakar S, Zandi K (2016). Antiviral activity of selected flavonoids against Chikungunya virus. ***Antiviral Research*****.** 133:50-61. [JCR IF: 4.00 (2 year 2025-2026)] (SJR 2024:Q1)

119. Clark MJ, Miduturu C, Schmidt AG, Zhu X, Pitts JD, Wang J, Potisopon S, Zhang J, Wojciechowski A, Chu JJH, Gray NS, Yang PL (2016). GNF-2 Inhibits Dengue Virus by Targeting Abl Kinases and the Viral E Protein. ***Cell Chemical Biology*****.** 23(4):443-452. [JCR IF: 7.20 (2 year 2025-2026)] (SJR 2024:Q1)

120. Teo FM, Chu JJH (2016). Diagnosis of human enteroviruses that cause hand, foot and mouth disease. ***Expert Review of Anti-infective Therapy*****.** 14(5):443-445. [JCR IF: 3.80 (2 year 2025-2026)] (SJR 2024: Q1)

121. Hussain KM, Lee RC, Ng MM, Chu JJH (2016). Establishment of a Novel Primary Human Skeletal Myoblast Cellular Model for Chikungunya Virus Infection and Pathogenesis. ***Scientific Reports*****.** 6:21406. [JCR IF: 3.90 (2 year 2025-2026)] (SJR 2024:Q1)

122. Suzuki Y, Chin WX, Han Q, Ichiyama K, Lee CH, Eyo ZW, Ebina H, Takahashi H, Takahashi C, Tan BH, Hishiki T, Ohba K, Matsuyama T, Koyanagi Y, Tan YJ, Sawasaki T, Chu JJH, Vasudevan SG, Sano K, Yamamoto N (2016). Characterization of RyDEN (C19orf66) as an Interferon-Stimulated Cellular Inhibitor against Dengue Virus Replication. ***PLoS Pathogens*****.** 12(1):e1005357. [JCR IF: 4.90 (2 year 2025-2026)] (SJR 2024:Q1)

123. Chen H, Parimelalagan M, Lai YL, Lee KS, Koay ES, Hapuarachchi HC, Ng LC, Ho PS, Chu JJH (2015). Development and Evaluation of a SYBR Green-Based Real-Time Multiplex RT-PCR Assay for Simultaneous Detection and Serotyping of Dengue and Chikungunya Viruses. ***Journal of Molecular Diagnostics*.** 17(6):722-728. [JCR IF: 3.40 (2 year 2025-2026)] (SJR 2024:Q1)

124. Wintachai P, Kaur P, Lee RC, Ramphan S, Kuadkitkan A, Wikan N, Ubol S, Roytrakul S, Chu JJH, Smith DR (2015). Activity of andrographolide against chikungunya virus infection. ***Scientific Reports***. 5:14179. [JCR IF: 3.90 (2 year 2025-2026)] (SJR 2024:Q1)

125. Lam S, Nyo M, Phuektes P, Yew CW, Tan YJ, Chu JJH (2015). A potent neutralizing IgM mAb targeting the N218 epitope on E2 protein protects against Chikungunya virus pathogenesis. ***MAbs***. 7(6):1178-94. [JCR IF: 7.30 (2 year 2025-2026)] (SJR 2024:Q1)

126. Bapat PR, Satav AR, Husain AA, Shekhawat SD, Kawle AP, Chu JJH, Purohit HJ, Daginawala HF, Taori GM, Kashyap RS (2015). Differential Levels of Alpha-2-Macroglobulin, Haptoglobin and Sero-Transferrin as Adjunct Markers for TB Diagnosis and Disease Progression in the Malnourished Tribal Population of Melghat, India. ***PLoS One***. 10(8):e0133928. [JCR IF: 2.60 (2 year 2025-2026)] (SJR 2024:Q1)

127. Chen J, Ng MM, Chu JJH (2015). Activation of TLR2 and TLR6 by Dengue NS1 Protein and Its Implications in the Immunopathogenesis of Dengue Virus Infection. ***PLoS Pathogens***. 11(7):e1005053. [JCR IF: 4.90 (2 year 2025-2026)] (SJR 2024:Q1)

128. Lam S, Chen H, Chen CK, Min N, Chu JJH (2015). Antiviral Phosphorodiamidate Morpholino Oligomers are Protective against Chikungunya Virus Infection on Cell-based and Murine Models. ***Scientific Reports***. 5:12727. [JCR IF: 3.90 (2 year 2025-2026)] (SJR 2024:Q1)

129. Yasamut U, Tongmuang N, Yenchitsomanus PT, Junking M, Noisakran S, Puttikhunt C, Chu JJH, Limjindaporn T (2015). Adaptor Protein 1A Facilitates Dengue Virus Replication. ***PLoS One***. 10(6):e0130065. [JCR IF: 2.60 (2 year 2025-2026)] (SJR 2024:Q1)

130. Lani R, Hassandarvish P, Chiam CW, Moghaddam E, Chu JJH, Rausalu K, Merits A, Higgs S, Vanlandingham D, Abu Bakar S, Zandi K (2015). Antiviral activity of silymarin against chikungunya virus. ***Scientific Reports***. 5:11421. [JCR IF: 3.90 (2 year 2025-2026)] (SJR 2024:Q1)

131. Chu JJH, Lee RC, Ang MJ, Wang WL, Lim HA, Wee JL, Joy J, Hill J, Chia BCS (2015). Antiviral activities of 15 dengue NS2B-NS3 protease inhibitors using a human cell-based viral quantification assay. ***Antiviral Research***. 118:68-74. [JCR IF: 4.00 (2 year 2025-2026)] (SJR 2024:Q1)

132. Ang MJ, Lau QY, Ng FM, Then SW, Poulsen A, Cheong YK, Ngoh ZX, Tan YW, Peng J, Keller TH, Hill J, Chu JJH, Brian Chia CS (2015). Peptidomimetic ethyl propenoate covalent

inhibitors of the enterovirus 71 3C protease: a P2-P4 study. ***Journal of Enzyme Inhibition and Medicinal Chemistry***. 4:1-8. [JCR IF: 5.51 (2 year 2025-2026)] (SJR 2024:Q2)

133. Leong SY, Ong BK, Chu JJH (2015). The role of Misshapen NCK-related kinase (MINK), a novel Ste20 family kinase, in the IRES-mediated protein translation of human enterovirus 71. ***PLoS Pathogens***. 11(3):e1004686. [JCR IF: 4.90 (2 year 2025-2026)] (SJR 2024:Q1)

134. Lee RC and Chu JJH (2015). Proteomics Profiling of Chikungunya-infected *Aedes albopictus* C6/36 cells Reveal Important Mosquito Cellular Factors in Virus Replication. ***PLoS Neglected Tropical Diseases*.** 9(3):e0003544. [JCR IF: 3.40 (2 year 2025-2026)] (SJR 2024:Q1)

135. Hinks J, Han PW, Chu JJH, Loo JS, Bazan GC, Hancock LE, Wuertz S (2015). Oligo-polyphenylenevinylene Conjugated Oligoelectrolyte Membrane Insertion Molecules Selectively Disrupt Cell Envelopes of Gram-positive Bacteria. ***Applied and Environmental Microbiology***. 81(6):1949-58. [JCR IF: 3.70 (2 year 2025-2026)] (SJR 2024:Q1)

136. Cheung YY, Chen KC, Chen H, Seng EK, Chu JJH (2014). Antiviral activity of lanatoside C against dengue virus infection. ***Antiviral Research***. 111:93-99. [JCR IF: 4.00 (2 year 2025-2026)] (SJR 2024:Q1)

137. Too HKI, Tan EL, Chu JJH (2014). Proteomic profiling of chikungunya virus-infected human muscle cells: reveal the role of cytoskeleton network in CHIKV replication. ***Journal of Proteomics***. 108:445-464. [JCR IF: 2.69 (2 year 2025-2026)] (SJR 2024:Q2)

138. Lim PJ, Chu JJH (2014). A Polarized Cell Model for Chikungunya Virus Infection: Entry and Egress of Virus Occurs at the Apical Domain of Polarized cells. ***PLoS Neglected Tropical Diseases***. 8(2):e2661. [JCR IF: 3.40 (2 year 2025-2026)] (SJR 2024:Q1)

139. Teo CS, Chu JJH (2014). Cellular Vimentin Regulates Construction of Dengue Virus Replication Complexes through the Interaction with NS4A Protein. ***Journal of Virology*.** 88(4):1897-1913. [JCR IF: 3.80 (2 year 2025-2026)] (SJR 2024:Q1)

140. Gupta DK, Kaur P, Leong ST, Tan LT, Prinsep MR, Chu JJH (2014). Anti-Chikungunya Viral Activities of Aplysiatoxin-Related Compounds from the Marine Cyanobacterium *Trichodesmium erythraeum*. ***Marine Drugs***. 12(1):115-27. [JCR IF: 5.40 (2 year 2025-2026)] (SJR 2024:Q1)

141. Ong SP, Ng ML, Chu JJH (2013). Differential regulation of angiopoietin 1 and angiopoietin 2 during dengue virus infection of human umbilical vein endothelial cells: implications for endothelial hyperpermeability. ***Medical Microbiology and Immunology***. 202(6):437-452. [JCR IF: 3.00 (2 year 2025-2026)] (SJR 2024:Q1)

142. Tan TY, Chu JJH (2013). Dengue virus-infected human monocytes trigger late activation of caspase-1, which mediates pro-inflammatory IL-1β secretion and pyroptosis. ***Journal of General Virology***. 94(Pt 10):2215-2220. [JCR IF: 4.08 (2 year 2025-2026)] (SJR 2024:Q2)

143. Chen KC, Kam YW, Lin RT, Ng MM, Ng LF, Chu JJH (2013). Comparative analysis of the genome sequences and replication profiles of chikungunya virus isolates within the East, Central and South African (ECSA) lineage. ***Virology Journal***. 10:169. [JCR IF: 3.80 (2 year 2025-2026)] (SJR 2024:Q1)

144. Kaur P, Chu JJH (2013). Chikungunya virus: an update on antiviral development and challenges**.** ***Drug Discovery Today*****.** 18(19-20):969-983. [JCR IF: 7.50 (2 year 2025-2026)] (SJR 2024:Q1)

145. Lee RC, Hapuarachchi HC, Chen KC, Hussain KM, Chen H, Low SL, Ng LC, Lin R, Ng MM, Chu JJH (2013). Mosquito Cellular Factors and Functions in Mediating the Infectious entry of Chikungunya Virus. ***PLoS Neglected Tropical Diseases***. 7(2):e2050. [JCR IF: 3.40 (2 year 2025-2026)] (SJR 2024:Q1)

146. Chen H, Takei F, Koay ES, Nakatani K, Chu JJH (2013). A Novel DANP-Coupled Hairpin RT-PCR for Rapid Detection of Chikungunya Virus. ***Journal of Molecular Diagnostics***. 15(2):227-233. [JCR IF: 3.40 (2 year 2025-2026)] (SJR 2024:Q1)

147. Kaur P, Thiruchelvan M, Lee RC, Chen H, Chen KC, Ng ML, Chu JJH (2013). Inhibition of chikungunya virus replication by harringtonine, a novel antiviral that suppresses viral protein expression. ***Antimicrobial Agents and Chemotherapy***. 57(1):155-167. [JCR IF: 4.50 (2 year 2025-2026)] (SJR 2024:Q1)

148. Zhao Y, Howe JL, Yu Z, Leong DT, Chu JJH, Loo JS, Ng KW (2013). Exposure to titanium dioxide nanoparticles induces autophagy in primary human keratinocytes. ***Small***. 9(3):387-392. [JCR IF: 12.10 (2 year 2025-2026)] (SJR 2024:Q1)

149. Lam S, Chen KC, Ng MM, Chu JJH (2012). Expression of plasmid-based shRNA against the E1 and nsP1 genes effectively silenced Chikungunya virus replication. ***PLoS* One**. 7(10):e46396. [JCR IF: 2.60 (2 year 2025-2026)] (SJR 2024:Q1)

150. Ong SP, Lee LM, Leong YF, Ng ML, Chu JJH (2012). Dengue virus infection mediates HMGB1 release from monocytes involving PCAF acetylase complex and induces vascular leakage in endothelial cells. ***PLoS One***. 7(7):e41932. [JCR IF: 2.60 (2 year 2025-2026)] (SJR 2024:Q1)

151. Karuppannan AK, Wu KX, Qiang J, Chu JJH, Kwang J (2012). Natural compounds inhibiting the replication of Porcine reproductive and respiratory syndrome virus. ***Antiviral Research***. 94(2):188-194. [JCR IF: 4.00 (2 year 2025-2026)] (SJR 2024:Q1)

152. Lim ME, Lee YL, Zhang Y and Chu JJH (2011). Photodynamic inactivation of viruses using upconversion nanoparticles. ***Biomaterials*****.** 33(6):1912-1920. [JCR IF: 12.90 (2 year 2025-2026)] (SJR 2024:Q1)

153. Low JSY, Wu KX, Chen KCY, Ng MML and Chu JJH (2011). Narasin, a novel antiviral compound that inhibits dengue virus protein expression. ***Antiviral Therapy***, 16(8): 1203-1218. [JCR IF: 2.1 (2025-2026)] (SJR 2024:Q2)

154. Hussain MK and Chu JJH (2011). Insights into the interplay between chikungunya virus and its human host. ***Future Virology***, 6(10): 1211-1223. [JCR IF: 1.39 (2 year 2025-2026)] (SJR 2024:Q3)

155. Leong JYS, Ng MML and Chu JJH (2011). Replication of Alphaviruses - A Review on the Entry Process of Alphaviruses into Cells. ***Advances in Virology***, Article ID No. 249640. [JCR IF: 1.44 (2025-2026)] (SJR 2024:Q3)

156. Ong SP and Chu JJH (2011). An update on the host factors contributing to vascular leakage during dengue virus infection. (Invited Editorial) ***Future Virology***, 6(2): 135-138 (Invited Editorial). [JCR IF: 1.39 (2 year 2025-2026)] (SJR 2024:Q3)

157. Hussain KM, Leong KL, Ng MM and Chu JJH (2011). The essential role of clathrin-mediated endocytosis in the infectious entry of human Enterovirus 71. ***Journal of Biological Chemistry*****,** 286(1):309-321. [JCR IF: 3.90 (2 year 2025-2026)] (SJR 2024:Q1)

158. Wu KX, Ng MM and Chu JJH (2010). Developments towards antiviral therapies against Enterovirus 71. ***Drug Discovery Today*****,** 15 (23-24):1041-1051. [JCR IF: 7.50 (2 year 2025-2026)] (SJR 2024:Q1)

159. Ang F, Wong AP, Ng L and Chu JJH (2010). Small interference RNA profiling reveals the essential role of human membrane trafficking genes in mediating the infectious entry of dengue virus. ***Virology Journal***, 7:24. [JCR IF: 3.80 (2 year 2025-2026)] (SJR 2024:Q1)

160. Ho PS, Ng ML, Chu JJH (2010). Establishment of one-step SYBR green-based real time-PCR assay for rapid detection and quantification of chikungunya virus infection. ***Virology Journal*****,** 7:13. [JCR IF: 3.80 (2 year 2025-2026)] (SJR 2024:Q1)

161. Azlinda, BA, Leong KW, Ng ML, CHU JJH and Garcia-Blanco MA (2009) The polypyrimidine tract binding protein is required for efficient dengue virus propagation and associates with the viral replication machinery. ***Journal of Biological Chemistry*****,** 284: 17021-17029. [JCR IF: 3.90 (2 year 2025-2026)] (SJR 2024:Q1)

162. Low JSY, Chen CK, Wu K, Ng ML and Chu JJH (2009) Antiviral Activity of Emetine Dihydrochloride against Dengue Virus Infection. ***Journal of Antivirals and Antiretrovirals*****,** 1(1): 062-071. [IF:5.32(2023)] (SJR 2023:Q4)

163. Chen JC, Ng ML and Chu JJH (2009). Molecular Profiling of T-Helper genes in mediating immunopathogenesis of dengue virus infection. ***Virology Journal*****,** 5:165. [JCR IF: 3.80 (2 year 2025-2026)] (SJR 2024:Q1)

164. Ong SP, Chu JJH and Ng ML (2008). Inhibition of West Nile virus replication in cells stably transfected with vector-based shRNA expression system. ***Virus Research*****,** 135(2): 292-297. [JCR IF: 2.70 (2 year 2025-2026)] (SJR 2024:Q2)

165. Hwang YC, Chu JJH, Yang PL, Chen W and Yates MV (2008). Rapid identification of inhibitors that interfere with poliovirus replication using a cell-based assay. ***Anti-Viral Research***, 77(3): 232-236. [JCR IF: 1.195 (2 year 2025-2026)] (SJR 2024:Q1)

166. Chu JJH and Ng ML (2008). Interplay of viral and host cellular factors in West Nile virus replication and pathogenesis. ***Future Virology***, 3(1), 17-23. [JCR IF: 1.39 (2 year 2025-2026)] (SJR 2024:Q3)

167. Chu JJH and Yang PL (2007). c-Src protein kinase inhibitors block the assembly and maturation of dengue virus. ***Proceedings of the National Academy of Sciences of the United States of America*****.** 104:3520-3525. [JCR IF: 9.10 (2 year 2025-2026)] (SJR 2024:Q1)

168. Chu JJH, Chiang CC and Ng ML (2007) Immunization of West Nile virus envelope glycoprotein domain III induced specific immune responses and protection against West Nile infection. ***Journal of Immunology*****,** 178:2699-2705. [JCR IF: 3.90 (2 year 2025-2026)] (SJR 2024:Q1)

169. Chin JF, Chu JJH and Ng ML (2007). The envelope glycoprotein domain III of Dengue virus serotypes 1 and 2 inhibit virus entry. ***Microbes and Infection*****,** 9:1-6. [JCR IF: 7.50 (2 year 2025-2026)] (SJR 2024:Q2)

170. Ong SP, Choo BGH, Chu JJH and Ng ML (2006) A vector-based small interfering RNA against West Nile virus infection. ***Anti-Viral Research*****,** 72:216-223. [JCR IF: 1.195 (2 year 2025-2026)] (SJR 2024:Q1)

171. Chu JJH, Leong PWH and Ng ML (2006) Analysis of the endocytic pathway mediating the infectious entry of mosquito-borne flavivirus West Nile into *Aedes albopictus* mosquito cells. ***Virology*****,** 349:463-475. [JCR IF: 8.30 (2 year 2025-2026)] (SJR 2024:Q2)

172. Lee JWM, Chu JJH and Ng ML (2006) Quantifying the specific binding between West Nile virus envelope domain III protein and the cellular receptor αVβ3 integrin. ***Journal of Biological Chemistry*****,** 281:1352-1360. [JCR IF: 3.90 (2 year 2025-2026)] (SJR 2024:Q1)

173. Chu JJH, Leong PWH and Ng ML (2005) Characterization of plasma membrane associated proteins from Aedes Albopictus mosquito (C6/36) cells that mediate West Nile virus binding and infection. ***Virology*****,** 339:249-260. [JCR IF: 8.30 (2 year 2025-2026)] (SJR 2024:Q2)

174. Chu JJH, Rajamanomani R, Li, J, Bhuvanakanathan R, Lescar J and Ng ML. (2005) Inhibition of West Nile virus entry using a recombinant domain III from envelope glycoprotein. ***Journal of General Virology*****,** 86:405-412. [JCR IF: 4.08 (2 year 2025-2026)] (SJR 2024:Q2)

175. Chu JJH and Ng ML (2004) Interaction of West Nile virus with αVβ3 integrin mediates virus entry into cells. ***Journal of Biological Chemistry***, 279:54533-54541. [JCR IF: 3.90 (2 year 2025-2026)] (SJR 2024:Q1)

176. Chu JJH and Ng ML (2004) Infectious entry of West Nile virus occurs through a clathrin-mediated endocytic pathway. ***Journal of Virology*****,** 78:10543-10555. [JCR IF: 3.80 (2 year 2025-2026)] (SJR 2024:Q1)

177. Chu JJH, Ng ML (2003) The mechanism of cell death during West Nile virus infection is dependent on initial infectious dose**.** ***Journal of General Virology***, 84(Pt 12):3305-3314. [JCR IF: 4.08 (2 year 2025-2026)] (SJR 2024:Q2)

178. Chu JJH, Choo BG, Lee JW, Ng ML (2003). Actin filaments participate in West Nile (Sarafend) virus maturation process. ***Journal of Medical Virology***, 71(3):463-472. [JCR IF: 4.60 (2 year 2025-2026)] (SJR 2024:Q1)

179. Chu JJH, Ng ML (2003). Characterization of a 105-kDa plasma membrane associated glycoprotein that is involved in West Nile virus binding and infection. ***Virology*****,** 312(2):458-469. [JCR IF: 8.30 (2 year 2025-2026)] (SJR 2024:Q2)

180. Chu JJH, Ng ML (2002). Trafficking mechanism of West Nile (Sarafend) virus structural proteins. ***Journal of Medical Virology***, 67(1):127-136. [JCR IF: 4.60 (2 year 2025-2026)] (SJR 2024:Q1)

181. Chu JJH, Ng ML (2002). Infection of polarized epithelial cells with flavivirus West Nile: polarized entry and egress of virus occur through the apical surface**.** ***Journal of General Virology***. 83(Pt 10):2427-2435. [JCR IF: 4.08 (2 year 2025-2026)] (SJR 2024:Q2)

182. Ng ML, Tan SH, Chu JJH (2001). Transport and budding at two distinct sites of visible nucleocapsids of West Nile (Sarafend) virus. ***Journal of Medical Virology***, 65(4):758-764. [JCR IF: 4.60 (2 year 2025-2026)] (SJR 2024:Q1)

Book Chapter And Other Publications

1. Yogarajah T, Chu JJH (2023) Construction of Infectious Clones for Human Enteroviruses. ***Methods in Molecular Biology-Reverse Genetics of RNA Viruses*** 2024:2733:155-174, https://doi.org/10.1007/978-1-0716-3533-9_10.

2. Joseph T, Phyu S , Thoe SYS, Chu JJH. (2022) Biorisk Management for SARS-CoV-2 Research in a Biosafety Level-3 Core Facility. ***Methods in Molecular Biology*** 2452:441-464, https://doi.org/10.1007/978-1-0716-2111-0_24.

3. Ng YL, Mok CK, Chu JJH. (2022) Cytopathic Effect (CPE)-Based Drug Screening Assay for SARS-CoV-2. ***Methods in Molecular Biology*** 2452:379-391, https://doi.org/10.1007/978-1-0716-2111-0_22.

4. Phuektes P, Chu JJH (2016). Reverse Genetics Approaches for Chikungunya Virus. ***Methods in Molecular Biology*****.** 1426:283-295.

5. Kaur P, Lee RC, Chu JJH (2016). Infectious Viral Quantification of Chikungunya Virus-Virus Plaque Assay. ***Methods in Molecular Biology*****.** 1426:93-103.

6. Ang SK, Lam S, Chu JJH (2016). Propagation of Chikungunya Virus Using Mosquito Cells. ***Methods in Molecular Biology*****.** 1426:87-92

7. Chia PY and Chu JJH (2012), Viral Encephalitis with Focus on Human Enteroviruses. ***Encephalitis*** edited by Sergey Tkachev, ISBN 978-953-51-0925-9, ISBN 980-953-30 ed. Intech Publisher, 2012.

8. Jackson S, Chu JJH, Chia PY, Morgan OC, Ng LC (2011). Dengue encephalitis. ***Flavivirus Encephalitis*** edited by Daniel Růžek, ISBN 978-953-307-669-0 ed. Chapter 4, Intech Publisher, 2011.

9. Chen KCY, Ong HM and Chu JJH (2010). Morphogenesis of Human Enterovirus 71: An Electron Microscopy Analysis Coupled with Immunogold Labelling Techniques. ***Microscopy: Science, Technology, Applications and Education*****.** (1): 66-74.

10. Chen JC, Chia PY, Ng ML and Chu JJH (2010). Antiviral Immunotherapy for mosquito-borne flaviviruses: a review of current status. ***Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry*****.** 10(1), 31-42.

11. Chia PY, Ng ML and Chu JJH (2010). Chikungunya fever: A review of a re-emerging mosquito-borne infectious disease and the current status. ***Current Research, Technology and Education Topics in Applied Microbiology and Microbial Biotechnology*****.** (1): 597-606.

12. Lee YL, Ng ML, Zhang Y and Chu JJH (2009). Novel photodynamic therapy of emerging and re-emerging medically important viruses. ***Asia Pacific Biotechnology*****.** 13(3), 24-27.

13. Ng ML, **Chu JJH** (2002). Interaction of West Nile and Kunjin viruses with cellular components during morphogenesis. In Current Topic in Microbiology and Immunology, ed. Mackenzie JS, Barrett ADT and Deubel V, 353 372. Current Topic in Microbiology and Immunology, vol. 267, ed. JS Mackenzie, ADT Barrett and V Deubel. New York: Springer, 2002. 20 pp.